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ABSTRACT
Purpose: Trachoma was suspected to be endemic in parts of the Democratic Republic of the
Congo (DRC). We aimed to estimate prevalences of trachomatous inflammation–follicular (TF),
trichiasis, and water and sanitation (WASH) indicators in suspected-endemic Health Zones.
Methods: A population-based prevalence survey was undertaken in each of 46 Health Zones
across nine provinces of DRC, using Global Trachoma Mapping Project methods. A two-stage
cluster random sampling design was used in each Health Zone, whereby 25 villages (clusters) and
30 households per cluster were sampled. Consenting eligible participants (children aged 1–9 years
and adults aged ≥15 years) were examined for trachoma by GTMP-certified graders; households
were assessed for access to WASH.
Results: A total of 32,758 households were surveyed, and 141,853 participants (98.2% of those
enumerated) were examined for trachoma. Health Zone-level TF prevalence in 1–9-year-olds
ranged from 1.9–41.6%. Among people aged ≥15 years, trichiasis prevalences ranged from
0.02–5.1% (95% CI 3.3–6.8). TF prevalence in 1–9-year-olds was ≥5% in 30 Health Zones, while
trichiasis prevalence was ≥0.2% in 37 Health Zones.
Conclusion: Trachoma is a public health problem in 39 of 46 Health Zones surveyed. To meet
elimination targets, 37 Health Zones require expanded trichiasis surgery services while 30 health
zones require antibiotics, facial cleanliness and environmental improvement interventions. Survey
data suggest that trachoma is widespread: further surveys are warranted.
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Introduction
Trachoma, a neglected tropical disease, is the most com-
mon infectious cause of blindness. The World Health
Organization (WHO) estimates that, globally, 200 million
people are at risk of trachoma; 1.9 million people are blind
or visually impaired from it; and 3.2 million people need
surgery to avoid trachomatous blindness, in 42 countries.1
Trachoma is considered to be a public health problem
where prevalence of trachomatous inflammation–follicular
(TF) in children aged 1–9 years is ≥5%, or trachomatous
trichiasis (TT) in people aged ≥15 years is ≥0.2%.2
Elimination of trachoma as a public health problem by
the year 2020 (through the surgery, antibiotics, facial
cleanliness and environmental improvement: “SAFE” strat-
egy) is a global target that was endorsed by the World
HealthAssembly in 1998.3,4 Prior to SAFE implementation,
baseline surveys of trachoma prevalence are recommended
to guide programs to deliver appropriate interventions.5
Trachoma has been suspected to be endemic in parts
of the Democratic Republic of the Congo (DRC), but
evidence to support program initiation has been lim-
ited. A review of medical records of 50,000 patients
attending the eye hospital in Kinshasa from 1962 to
1979 concluded that trachoma was absent from the list
of common blinding eye diseases.6 Between 1987 and
1991, Ukety documented 15 cases of trichiasis in areas
of northeastern DRC (then Zaire), near the border with
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Uganda.7 In 2013, analyses of the geographic distribu-
tion of trachoma in Africa based on data from the
Global Atlas of Trachoma (http://www.trachomaatlas.
org) suggested that areas of DRC bordering Central
African Republic, South Sudan and Zambia might also
be endemic for trachoma (Figure 1).8
With only a few years to go before the 2020 target for
global elimination of trachoma, mapping in areas sus-
pected to be trachoma-endemic is essential for planning
SAFE implementation. The population-based prevalence
surveys reported here, conducted as part of the Global
Trachoma Mapping Project (GTMP), aimed to estimate:
the prevalence of TF in children aged 1–9 years; the pre-
valence of trichiasis in people aged ≥15 years; and key
household-level water, sanitation and hygiene (WASH)
indicators in suspected-endemic Health Zones of DRC.
Materials and methods
The GTMP methodology
The study was conducted using the methods of the
GTMP.9,10 In brief, in each survey, in addition to indi-
vidual-level demographic and clinical data, household-
level WASH data were entered into the purpose-built
LINKS application on Android smartphones, trans-
mitted to the Cloud, then managed and reviewed by
health ministries, as previously described.10 The main
outcome measures were the prevalence of TF in chil-
dren aged 1–9 years, prevalence of trichiasis in adults
aged ≥15 years, percentage of households using safe
methods for disposal of human feces, and percentage
of households with proximate access to water for per-
sonal hygiene purposes, all at Health Zone level.
Figure 1. Prevalence of trachomatous inflammation–follicular (TF) in countries bordering Democratic Republic of the Congo, based
on Global Trachoma Atlas data in 2013.
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Study settings
The surveys were undertaken from 2014 to 2016.
Figure 2 shows the nine provinces (Nord-Ubangi,
Sud-Ubangi, Bas-Uele, Haut-Uele, Ituri, Nord-Kivu,
Sud-Kivu, Tanganika and Haut-Katanga) in which sur-
veys were undertaken. A total of 46 Health Zones
(defined as the operational unit for primary health
care in DRC and encompassing populations of
100,000–150,000) were prioritized for surveys in the
nine provinces, based on desk reviews, which included:
(1) review of Global Atlas of Trachoma (www.tracho
maatlas.org) data on trachoma prevalence in areas bor-
dering DRC (Figure 1); (2) review of local clinical
reports on trachoma; (3) questionnaire-based surveys
of health care workers (in Nord-Ubangi, Sud-Ubangi,
Bas-Uele, Haut-Uele, Ituri, Nord-Kivu and Sud-Kivu)
enquiring about trichiasis cases seen; and (4) question-
naire-based surveys of key informants in the commu-
nity (in Nord-Kivu and Sud-Kivu) enquiring about the
presence of trichiasis. Based on inputs (1), (3) and (4),
Health Zones in which (an arbitrarily-defined) five or
more cases of trichiasis had been seen, and Health
Zones bordering trachoma-endemic areas of Central
African Republic (Nord-Ubangi, Sud-Ubangi, Bas-
Uele), Uganda (Ituri) and Zambia (Haut-Katanga and
Tanganika) were prioritized for trachoma surveys.
Sample size estimation
To estimate the Health Zone-level TF prevalence in chil-
dren aged 1–9 years, the sample size was calculated using
an expected prevalence of 10%, powering each survey to
have 95% confidence of estimating that prevalence with
absolute precision of ±3%. We included a design effect of
2.65, which resulted in a sample size estimate of 1019
children, then inflated that estimate by 20% to allow for
expected non-response. The number of households
needed in each Health Zone was the number calculated
to house 1222 children aged 1–9 years.10 Given that 33%
of the DRC population is aged 1–9 years, and a rural DRC
household has a mean of 5.1 inhabitants,11 we estimated
that it was necessary to sample at least 727 households. If a
team with one grader and one recorder could sample 30
households per day, 25 clusters (total 750 households)
were needed in order to reach the required sample size.
Although we also aimed to estimate trichiasis prevalence
in ≥15-year-olds, sample sizes were calculated based only
on parameters relating to TF in children; the low preva-
lence of trichiasis means that accurately estimating its
prevalence requires substantially larger samples. Having
determined the number of households required to recruit
sufficient children to estimate TF prevalence as above, the
sample of ≥15-year-olds used for estimating trichiasis
prevalence was set as the adults living in those same
households.10 For WASH indicators, the sample size was
calculated to estimate a proportion of 50% of households
with each indicator of interest, with absolute precision of
±7%, a design effect of 3 and inflation by 20% to account
for non-response, resulting in a sample size of 735 house-
holds per Health Zone. Therefore, all households sampled
were assessed for access to WASH.
Sample selection
Selection of clusters
A two-stage cluster random sampling design was used.
Clusters were defined as villages, the smallest
Figure 2. Location of provinces and health zones surveyed and prevalence of (a) trachomatous inflammation–follicular (TF) in
children aged 1–9 years, and (b) trichiasis in adults aged ≥15 years, Global Trachoma Mapping Project, Democratic Republic of the
Congo, 2014–2016.
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administrative unit in DRC. The list of villages in each
Health Zone was obtained from provincial health
offices. In the first sampling stage, 25 villages were
systematically selected, with probability proportional
to population size, using computer-generated random
starting points.
Selection of households and participants
In the second sampling stage, 30 households were
selected using the compact segment sampling method.
A household was defined as persons living together and
eating from the same pot. Each village was divided into
segments of approximately 30 households. A single
segment was then selected by random draw. Within
the selected segment, all households were visited, and
all eligible household participants (children aged 1–9
years and people aged ≥15 years) were examined for
trachoma.
Household interviews
Household interviews on water sanitation and hygiene
(WASH) were undertaken by trained recorders using a
standard questionnaire.10 Heads of households were
asked about types of water sources used, distance to
water sources, and type of sanitation facilities used by
adults of the household; when the family reported using
a latrine, the latrine type was verified by observation.
Trachoma grading
Graders participating in the surveys had obtained a
kappa for diagnosing TF of at least 0.7 in a formal
inter-grader agreement test (based on a sample of 50
children), compared to a GTMP-certified grader
trainer.9 The eyelid and tarsal conjunctiva of each eye
were examined using a 2.5× magnifying loupe and
torch or sunlight, looking for signs of active trachoma
and trichiasis.
Data management and analysis
Data were collected electronically using Android smart-
phones and the LINKS system (https://gtmp.linkssys
tem.org/drc) customized for the GTMP.9,10
Descriptive statistics were used to examine sample
characteristics, prevalence of trachoma and proportion
of households with key WASH indicators. WASH data
were categorized based on WHO/UNICEF Joint
Monitoring Program definitions for improved and
unimproved water sources and sanitation facilities
(https://www.wssinfo.org/definitions-methods/watsan-
categories/). Prevalence estimates and 95% confidence
intervals for TF and trichiasis were generated using
GTMP methods in R (R Foundation for Statistical
Computing, Vienna, Austria) and Structured Query
Language (SQL). For each cluster, the proportion of
1–9-year-olds with TF was adjusted for age, using
data from the most recent census. Similarly, for each
cluster, the proportion of ≥15-year-olds with trichiasis
was adjusted for age and gender.10 Health Zone-level
prevalences of each sign were calculated as the mean of
the adjusted cluster-level proportions, and confidence
intervals were calculated by bootstrapping, with 10,000
replications. Associations of TF and WASH indicators
were explored using Spearman’s rank test. To investi-
gate differences in estimated WASH coverage with
previous estimates, overall proportions of WASH indi-
cators pooled from the 46 surveys were compared with
national-level 2013–2014 Demographic and Health
Survey (DHS) data from DRC’s rural population,11
using a two-sample test of proportions.
Ethical considerations
Prior to the surveys, approval was obtained from the
ethics committee of the London School of Hygiene &
Tropical Medicine (reference 6319). Because the pur-
pose of the data collection was programmatic rather
than for research, the DRC Ministère de la Santé
Publique ruled that local ethics committee review was
not required (reference MS.1251/SG/EKA/2283/MK/
2014). Verbal consent to participate in the survey was
given by the head of each selected household; informed
verbal consent for examination was given by each par-
ticipant or their parent or guardian.
Results
Characteristics of survey population
Table 1 summarizes the characteristics of the popula-
tion sampled, by Health Zone. Our teams examined a
total of 141,853 participants (98.2% of those enum-
erated) in 32,758 households. A total of 83,247 chil-
dren aged 1–9 years and 58,606 people aged ≥15
years were examined for TF and trichiasis, respec-
tively. For all 46 surveys combined, the proportions
of male participants among children aged 1–9 years
and people aged ≥15 years were 49.7% and 41.9%,
respectively. The mean ages (and standard devia-
tions) among children aged 1–9 years and people
aged ≥15 years were 4.9 years (2.5) and 34.5 years
(15.2), respectively.
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Prevalence of trachoma
Health Zone-level prevalences of trachoma are shown
in Table 2 and Figure 2. Prevalence of TF was ≥5% in
30 Health Zones, of which 11 had TF prevalences of
5.0–9.9%; 18 had TF prevalences of 10.0–29.9%; and
one had a TF prevalence ≥30%. Trichiasis prevalence
was ≥0.2% in 37 Health Zones.
Prevalence of access to water, sanitation, and
hygiene
Table 3 summarizes key indicators on access to WASH.
The overall proportion of households that: (1) reported
using an improved drinking water source was 44.9%
(range by Health Zone, 3–95); (2) had drinking water
source in the household yard or within 1 km of it was
64.7% (range by Health Zone, 39–96); and (3) had
access to improved sanitation facilities was 13.8%
(range by Health Zone, 0–96). In the majority (54%)
of Health Zones, the proportion of households with
access to improved sanitation facilities was <10%.
Health Zone-level TF prevalence was not correlated
with any of the main WASH indicators: proportion of
households with improved drinking water source (p =
0.19); proportion of households with drinking water
source in the yard or within 1 km (p = 0.25); and
proportion of households with sanitation facilities (p
= 0.16). Compared to national-level DHS estimates for
the rural population of DRC, proportions of house-
holds with access to improved water sources (DHS
32.2% vs. GTMP 48.9%; test of proportions, p <
Table 1. Characteristics of survey population by Health Zone, Global Trachoma Mapping Project, Democratic Republic of the Congo,
2014–2016.
Children aged 1–9 years Adults aged ≥15 years
Province Health Zone Number of households sampled Number examined Proportion male (%) Number examined Proportion male (%)
Nord-Ubangi Bili 631 1425 50.2 1367 45.9
Nord-Ubangi Bosobolo 647 1663 49.4 1335 47.9
Nord-Ubangi Karawa 759 2048 54.5 1345 47.1
Nord-Ubangi Mobayi 768 2134 51.6 1606 48.2
Nord-Ubangi Yakoma 753 2137 49.8 859 37.8
Sud-Ubangi Libenge 747 1943 51.5 1016 47.1
Sud-Ubangi Zongo 737 1942 51.1 1493 45.9
Bas-Uele Bili 711 1573 49.8 1284 43.2
Bas-Uele Bondo 648 1624 53.3 1401 42.6
Bas-Uele Monga 735 1820 52.1 1168 50.4
Haut-Uele Pawa 671 1702 50.7 1499 44.2
Ituri Angumu 625 1579 49.6 868 32.4
Ituri Drodro 693 1594 52.6 776 39.7
Ituri Nyarambe 607 1465 51.9 829 32.1
Ituri Aungba 756 1604 50.8 1267 37.8
Ituri Bambu 676 1636 48.0 1202 37.3
Ituri Fataki 701 1623 50.5 1293 35.8
Ituri Ghety 689 2016 52.0 1452 31.7
Ituri Jiba 701 1522 49.4 1315 36.5
Ituri Lita 675 1698 48.6 1148 34.3
Ituri Mahagi 719 1658 51.9 1300 38.8
Ituri Mambasa 680 1624 52.7 1149 39.4
Ituri Rethy 693 1653 51.4 1361 34.3
Nord Kivu Binza 747 2082 51.4 1229 47.5
Nord-Kivu Birambizo 766 2153 50.4 1363 44.2
Nord-Kivu Katoyi 785 1994 47.7 1318 43.8
Nord-Kivu Kayna 754 2160 49.3 1495 42.1
Nord-Kivu Kibirizi 748 1983 48.4 1358 42.2
Nord-Kivu Kibua 754 2021 48.0 1467 47.3
Nord-Kivu Masisi 741 1848 49.6 1358 51.3
Nord-Kivu Walikale 749 2140 48.9 1536 45.1
Sud-Kivu Bunyakiri 739 2005 49.9 1180 36.5
Sud-Kivu Kadutu 751 1965 46.3 1351 40.9
Sud-Kivu Kalehe 749 1928 51.1 1361 42.9
Sud-Kivu Kalole 756 2010 47.0 1569 50.0
Sud-Kivu Kitutu 750 1934 44.3 1428 44.8
Sud-Kivu Minova 758 2081 48.0 1434 39.3
Sud-Kivu Mwana 720 1772 48.6 1387 44.8
Sud-Kivu Mwenga 756 1937 44.6 1531 45.3
Sud-Kivu Nyantende 741 1743 47.1 1467 47.3
Haut-Katanga Kilwa 731 1674 51.0 1233 47.2
Haut-Katanga Kipushi 705 1789 49.2 928 33.9
Haut-Katanga Kasenga 631 1796 49.1 1081 30.7
Haut-Katanga Pweto 609 1355 47.2 1084 40.6
Haut-Katanga Sakania 669 1588 49.4 1003 25.5
Tanganika Moba 627 1606 48.6 1112 36.0
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0.001) and with drinking water sources in the yard or
within 1 km distance (DHS 41.8% vs. GTMP 64.7%;
test of proportions, p < 0.001) were higher in our
surveys overall. However, the proportion of households
with access to improved sanitation facilities was lower
in our surveys (DHS 17.1% vs. GTMP 13.8%; test of
proportions, p < 0.001).
Discussion
To achieve trachoma elimination, timely baseline sur-
veys of trachoma in suspected-endemic districts are
vital for planning SAFE interventions. Our findings
suggest that trichiasis is widespread in surveyed areas
of DRC, and public health-level actions to provide
surgery services are required in 37 Health Zones in
which trichiasis prevalences in adults were ≥0.2%.
Based on TF prevalences, a total of 30 Health Zones
are eligible for mass drug administration (MDA) with
azithromycin before repeat prevalence surveys, as fol-
lows: a single dose for all residents of the 11 Health
Zones with TF prevalences of 5.0–9.9%; three annual
rounds in 18 Health Zones with TF prevalences of
10.0–29.9%; and five annual rounds in one Health
Table 2. Prevalence of trachoma by Health Zone, Global
Trachoma Mapping Project, Democratic Republic of the
Congo, 2014–2016.
Province
Health
Zone
Prevalence of TF %
in children aged
1–9 years (95% CI)a
Prevalence of
trichiasis % in adults
aged ≥15 years
(95% CI)b
Nord-Ubangi Bili 15.2 (10.6–20.2) 1.55 (0.69–2.75)
Nord-Ubangi Bosobolo 10.0 (8.1–12.3) 1.52 (1.07–2.10)
Nord-Ubangi Karawa 11.4 (9.0–13.4) 0.21 (0.05–0.45)
Nord-Ubangi Mobayi 17.6 (12.5–23.4) 0.45 (0.16–0.88)
Nord-Ubangi Yakoma 8.3 (6.6–10.1) 2.55 (1.12–4.67)
Sud-Ubangi Libenge 14.5 (10.8–19.1) 1.66 (0.39–3.52)
Sud-Ubangi Zongo 10.2 (7.2–14.5) 0.76 (0.20–1.66)
Bas-Uele Bili 12.7 (10.4–14.7) 1.05 (0.64–1.54)
Bas-Uele Monga 3.5 (2.1–5.0) 0.99 (0.28–1.95)
Bas-Uele Bondo 4.7 (2.6–7.2) 2.04 (1.01–3.05)
Haut-Uele Pawa 7.4 (5.6–9.2) 4.00 (2.39–5.74)
Ituri Angumu 9.5 (7.9–11.1) 5.09 (3.28–6.76)
Ituri Drodro 6.0 (3.9–8.7) 1.16 (0.70–1.76)
Ituri Nyarambe 8.8 (6.1–11.8) 2.47 (1.28–4.00)
Ituri Aungba 8.5 (6.5–10.9) 0.18 (0.05–0.35)
Ituri Bambu 19.3 (15.6–23.7) 3.86 (2.64–5.46)
Ituri Fataki 3.5 (2.1–5.3) 0.59 (0.13–1.46)
Ituri Ghety 18.6 (16.5–20.9) 2.76 (1.94–3.50)
Ituri Jiba 7.5 (5.0–10.3) 0.77 (0.38–1.21)
Ituri Lita 19.4 (16.7–23.3) 2.87 (1.83–4.25)
Ituri Mahagi 5.8 (3.3–8.3) 0.08 (0.00–0.19)
Ituri Mambasa 10.2 (8.0–11.7) 1.46 (0.86–2.01)
Ituri Rethy 3.9 (2.3–6.1) 0.22 (0.06–0.45)
Nord-Kivu Binza 11.1 (9.2–13.6) 1.00 (0.61–1.53)
Nord-Kivu Birambizo 6.6 (4.9–8.3) 0.42 (0.20–0.70)
Nord-Kivu Katoyi 17.6 (15.6–20.4) 1.08 (0.70–1.49)
Nord-Kivu Kayna 1.9 (0.9–3.2) 0.16 (0.04–0.34)
Nord-Kivu Kibirizi 3.0 (1.6–5.0) 0.15 (0.00–0.37)
Nord-Kivu Kibua 2.0 (1.2–3.1) 0.08 (0.00–0.18)
Nord-Kivu Masisi 4.8 (2.5–8.2) 0.13 (0.03–0.30)
Nord-Kivu Walikale 2.1 (1.2–3.1) 0.02 (0.00–0.05)
Sud-Kivu Bunyakiri 6.6 (4.1–9.0) 0.48 (0.23–0.69)
Sud-Kivu Kadutu 4.5 (3.3–5.9) 0.23 (0.04–0.49)
Sud-Kivu Kalehe 11.7 (8.3–16.5) 0.95 (0.62–1.32)
Sud-Kivu Kalole 2.0 (0.6–3.6) 0.13 (0.03–0.26)
Sud-Kivu Kitutu 3.0 (1.8–4.7) 0.65 (0.26–1.28)
Sud-Kivu Minova 15.2 (10.6–21.1) 1.10 (0.54–1.81)
Sud-Kivu Mwana 3.3 (1.5–5.7) 1.31 (0.73–2.12)
Sud-Kivu Mwenga 2.1 (1.2–3.2) 1.70 (0.62–3.60)
Sud-Kivu Nyantende 2.2 (1.2–3.2) 0.11 (0.00–0.29)
Haut-Katanga Kilwa 13.7 (9.6–17.3) 0.65 (0.33–1.05)
Haut-Katanga Kipushi 16.9 (8.0–25.5) 0.90 (0.07–2.00)
Haut-Katanga Kasenga 9.2 (7.4–11.3) 0.47 (0.22–0.72)
Haut-Katanga Pweto 41.6 (32.4–50.6) 2.85 (1.92–4.08)
Haut-Katanga Sakania 2.5 (1.2–4.4) 0.20 (0.01–0.53)
Tanganika Moba 15.3 (12.6–18.6) 3.33 (1.93–5.05)
aAdjusted for age, in 1-year bands.
bAdjusted for gender and age, in 5-year bands.
CI, confidence interval.
Table 3. Proportion of households with key water, sanitation
and hygiene indicators, by Health Zone, Global Trachoma
Mapping Project, Democratic Republic of the Congo,
2014–2016.
Province
Health
Zone
Proportion of households (%)
Using
improved
drinking
water source
With drinking
water source in
yard/within
1 km
With
improved
sanitation
facilities
Nord-Ubangi Bili 4.9 73.7 3.0
Nord-Ubangi Bosobolo 8.5 57.5 0.9
Nord-Ubangi Karawa 28.5 58.6 0.00
Nord-Ubangi Mobayi 26.7 62.0 0.1
Nord-Ubangi Yakoma 8.1 73.0 9.0
Sud-Ubangi Libenge 41.4 71.6 11.2
Sud-Ubangi Zongo 24.3 46.8 0.5
Bas-Uele Bili 3.0 52.9 0.1
Bas-Uele Bondo 3.5 80.9 22.5
Bas-Uele Monga 4.1 69.0 24.6
Haut-Uele Pawa 8.6 84.1 27.1
Ituri Angumu 29.4 65.6 20.6
Ituri Drodro 35.9 58.9 19.7
Ituri Nyarambe 55.8 55.8 12.4
Ituri Aungba 29.9 76.1 17.7
Ituri Bambu 28.0 50.1 7.0
Ituri Fataki 74.0 69.9 24.1
Ituri Ghety 45.1 52.1 0.1
Ituri Jiba 64.2 76.0 22.3
Ituri Lita 45.9 39.4 0.1
Ituri Mahagi 66.2 81.4 20.7
Ituri Mambasa 33.8 59.7 0.0
Ituri Rethy 76.6 57.9 20.6
Nord Kivu Binza 44.2 95.6 0.5
Nord-Kivu Birambizo 44.1 48.0 2.6
Nord-Kivu Katoyi 31.5 58.7 3.8
Nord-Kivu Kayna 59.0 57.2 4.9
Nord-Kivu Kibirizi 40.9 57.8 0.4
Nord-Kivu Kibua 62.7 67.4 9.7
Nord-Kivu Masisi 76.9 49.4 2.4
Nord-Kivu Walikale 35.8 68.6 9.6
Sud-Kivu Bunyakiri 69.1 80.1 28.4
Sud-Kivu Kadutu 94.9 91.9 63.5
Sud-Kivu Kalehe 84.4 78.9 25.1
Sud-Kivu Kalole 22.6 81.7 13.8
Sud-Kivu Kitutu 68.7 53.5 1.5
Sud-Kivu Minova 78.2 65.8 29.2
Sud-Kivu Mwana 59.7 56.8 1.2
Sud-Kivu Mwenga 62.8 63.9 1.7
Sud-Kivu Nyantende 88.0 50.1 3.8
Haut Katanga Kilwa 59.0 58.7 17.5
Haut-Katanga Kipushi 80.6 74.9 61.4
Haut-Katanga Kasenga 26.0 43.6 42.6
Haut-Katanga Pweto 30.7 60.3 6.9
Haut-Katanga Sakania 25.9 82.2 42.9
Tanganika Moba 50.7 52.5 1.4
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Zone with TF prevalence ≥30%. While access to WASH
varied markedly by Health Zone, overall, less than half
of all households reported using an improved drinking
water source, and less than 2 in 10 households had an
improved sanitation facility. Therefore, implementation
of the F and E components of SAFE should be a
priority, for the sake of more than just elimination of
trachoma.12,13
The surveys reported here used methods recom-
mended by WHO for sampling of populations and
examination for trachoma.10 However, there are a
number of limitations. First, despite the low proportion
(1.8%) of eligible participants recorded as being absent
from surveyed households, in most Health Zones, a
substantial proportion of adult men refused to partici-
pate in the surveys and declined even to have their
existence recorded. While the relative paucity of adult
men is a potential source of bias and might tend to
overestimate the prevalence of trichiasis (given that
trichiasis is generally more common in women than
men),14 standardization of prevalence estimates by age
and gender was intended to minimize—but does not
negate—this bias. Second, recent evidence from
Ethiopia suggests that trichiasis is frequently attributa-
ble to metaplastic or misdirected eyelashes,15 often
from aetiologies other than trachoma. However, in the
DRC surveys, we did not examine eyes with trichiasis
for trachomatous conjunctival scarring (TS),16 so we
report in this paper prevalences of any-trichiasis (with
or without TS). Management strategies for non-tracho-
matous trichiasis are less well defined than for tracho-
matous trichiasis, and the background prevalence of
non-trachomatous trichiasis in trachoma-endemic or
non-trachoma-endemic environments is presently
unknown. Awareness of the potential importance of
non-trachomatous trichiasis to estimates of the preva-
lence of trachoma has arisen only relatively recently.17
Generation of estimates of any-trichiasis at baseline
does not necessarily impact on planning SAFE imple-
mentation, depending on national policies for the man-
agement of non-trachomatous trichiasis, but may
represent over-estimates for the purposes of determin-
ing whether elimination goals have been reached.
Methods for trachoma impact surveys have now been
refined to include examination for TS in eyes with
trichiasis, thus allowing distinction between non-tra-
chomatous and trachomatous disease.18 Finally, the
GTMP acknowledges that estimates of TT prevalence
lack ideal precision.10 We present our confidence inter-
vals here, and continue to work on ways to better
determine the population frequency of this low preva-
lence condition, which is an epidemiological problem
that is not unique to trachoma.
Compared to rural WASH indicators from DHS
2013–2014,11 households in our series of surveys had
better access to improved water sources but worse
access to improved sanitation facilities. Our methods
for assessment of WASH were consistent with those of
the DHS, as specified by the WHO/UNICEF Joint
Monitoring Program. It is worth noting that our sur-
veys are far more granular than the DHS, and covered
only a small proportion of the country, whereas DHS
data were designed to be representative at national
level. In other words, these discrepancies probably
reflect real differences in WASH access for our popula-
tions compared to national means.
These surveys were undertaken in 46 priority Health
Zones in which trachoma was suspected to be endemic,
based on the preceding desk reviews. It may be inferred
from our results that we have not yet found the edges of
the endemic foci, and therefore that further baseline
surveys should be considered. Priority could be given to
Health Zones bordering those with prevalences of TF
≥10% or of trichiasis ≥1%. In Health Zones bordering
surveyed areas with TF prevalences of 5.0–9.9% or
trichiasis prevalences of 0.2–0.9%, trachoma rapid
assessments could be considered to help determine
whether further formal surveys are needed.19
The survey findings reported here suggest that 30
Health Zones qualify for mass drug administration with
azithromycin and implementation of the F&E compo-
nents of SAFE for trachoma elimination purposes,
while public health-level action to deliver trichiasis
surgery is needed in 37 Health Zones. These important
findings will facilitate planning SAFE interventions and
elimination of trachoma from DRC. In addition, we
note that further baseline surveys in DRC are required.
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